Pharmacology of Mefenamic Acid

Introduction/Overview

Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) belonging to the fenamate class, which has been utilized in clinical practice for several decades. It is distinguished from other NSAIDs by its specific chemical structure and certain pharmacodynamic properties. The drug serves as a prototype for understanding the pharmacology of anthranilic acid derivatives and continues to be relevant in specific therapeutic contexts, particularly for the short-term management of pain and inflammation. Its clinical application, while more limited in scope compared to broader-spectrum NSAIDs like ibuprofen or naproxen, offers a valuable case study in the selective use of anti-inflammatory agents based on patient-specific factors and therapeutic goals.

The clinical relevance of mefenamic acid persists primarily in the management of dysmenorrhea and mild to moderate pain. Its importance in the pharmacological armamentarium lies not only in its therapeutic effects but also in the characteristic adverse effect profile associated with fenamates, which necessitates prudent prescribing. Understanding its pharmacology is essential for healthcare professionals to optimize therapeutic outcomes while minimizing risks, particularly those related to gastrointestinal and renal toxicity common to NSAIDs as a class.

Learning Objectives

• Classify mefenamic acid within the broader categories of non-steroidal anti-inflammatory drugs and describe its unique chemical structure as a fenamate.
• Explain the detailed mechanism of action, including its dual inhibition of cyclooxygenase enzymes and possible effects on prostaglandin receptor antagonism.
• Outline the pharmacokinetic profile of mefenamic acid, including absorption, distribution, metabolism, excretion, and the implications for its dosing regimen.
• Identify the approved therapeutic indications, common adverse effects, serious toxicities, and major drug interactions associated with mefenamic acid therapy.
• Apply knowledge of special population considerations, including use in pregnancy, lactation, pediatrics, geriatrics, and patients with renal or hepatic impairment, to clinical decision-making.

Classification

Mefenamic acid is systematically classified within multiple hierarchical categories relevant to pharmacology and therapeutics.

Therapeutic and Pharmacological Classification

The primary classification of mefenamic acid is as a non-steroidal anti-inflammatory drug (NSAID). Within this broad class, it is further specified as an analgesic, antipyretic, and anti-inflammatory agent. Its therapeutic actions are non-opioid and non-hormonal in nature.

Chemical Classification

Chemically, mefenamic acid is a member of the fenamate or anthranilic acid derivative family. This group is characterized by an N-aryl anthranilic acid structure. The specific chemical name for mefenamic acid is 2-[(2,3-dimethylphenyl)amino]benzoic acid. Its molecular structure consists of a benzoic acid moiety linked to a 2,3-dimethylphenylamine group. This anthranilic acid backbone differentiates it from other NSAID classes such as propionic acids (e.g., ibuprofen, naproxen), acetic acids (e.g., diclofenac, indomethacin), and enolic acids (e.g., piroxicam, meloxicam). The fenamate structure is associated with the drug’s particular pharmacokinetic and pharmacodynamic profile, including its relatively short half-life and its proposed additional mechanism of prostaglandin receptor blockade.

Mechanism of Action

The primary mechanism of action of mefenamic acid, shared with other traditional NSAIDs, is the inhibition of prostaglandin synthesis. However, evidence suggests additional modulatory effects that may contribute to its overall pharmacological profile.

Inhibition of Cyclooxygenase (COX) Enzymes

The cornerstone of mefenamic acid’s action is the reversible, competitive inhibition of the enzyme cyclooxygenase (COX), also known as prostaglandin-endoperoxide synthase (PTGS). This enzyme exists in at least two major isoforms: COX-1 and COX-2. COX-1 is constitutively expressed in most tissues and is involved in physiological functions such as gastric cytoprotection, platelet aggregation, and renal blood flow regulation. COX-2 is primarily induced at sites of inflammation by cytokines and growth factors, playing a key role in producing prostanoids that mediate pain, fever, and inflammation.

Mefenamic acid is considered a non-selective COX inhibitor. It inhibits both COX-1 and COX-2 isoforms, though its relative potency may vary. The inhibition occurs by competing with the substrate, arachidonic acid, for binding to the active site of the COX enzyme. By binding to this site, mefenamic acid prevents the conversion of arachidonic acid to prostaglandin G₂ (PGG₂) and subsequently to prostaglandin H₂ (PGH₂). PGH₂ is the common precursor for a cascade of other prostanoids, including prostaglandin E₂ (PGE₂), prostaglandin I₂ (PGI₂, prostacyclin), prostaglandin F_2α (PGF_2α), and thromboxane A₂ (TXA₂). The reduction in the synthesis of these mediators, particularly PGE₂ and PGI₂ at inflammatory sites, accounts for the drug’s anti-inflammatory, analgesic, and antipyretic effects.

Potential Prostaglandin Receptor Antagonism

In addition to enzyme inhibition, in vitro studies suggest that mefenamic acid and other fenamates may act as direct antagonists at certain prostaglandin receptors, specifically the EP₁ receptor subtype. PGE₂ exerts its diverse effects by binding to four G-protein-coupled receptor subtypes (EP₁-EP₄). The EP₁ receptor is implicated in mediating pain perception and certain smooth muscle contractions. By blocking this receptor, mefenamic acid could potentially provide an additional layer of analgesic action independent of COX inhibition. However, the clinical significance of this receptor antagonism at therapeutic plasma concentrations in humans remains an area of investigation and is not considered the dominant mechanism.

Cellular and Molecular Consequences

The inhibition of prostaglandin synthesis leads to several downstream effects. At the site of tissue injury or inflammation, reduced PGE₂ diminishes vasodilation and edema, lowers the sensitivity of pain receptors (nociceptors) to mechanical and chemical stimuli, and decreases the recruitment and activity of inflammatory cells. In the hypothalamus, a reduction in PGE₂ resets the elevated temperature set-point, leading to vasodilation and heat loss, which manifests as an antipyretic effect. In platelets, inhibition of COX-1 reduces the synthesis of thromboxane A₂, a potent promoter of platelet aggregation. However, due to mefenamic acid’s reversible binding and short residence time on the enzyme, its antiplatelet effect is transient and less pronounced than that of irreversible inhibitors like aspirin.

Pharmacokinetics

The pharmacokinetic profile of mefenamic acid influences its dosing schedule, onset of action, and potential for interactions and toxicity.

Absorption

Mefenamic acid is administered orally and is rapidly absorbed from the gastrointestinal tract. Absorption is generally efficient, with peak plasma concentrations (C_max) typically achieved within 2 to 4 hours (T_max) following a single dose. The presence of food may delay the rate of absorption, slightly prolonging T_max, but does not appear to significantly reduce the overall extent of absorption (bioavailability). The drug’s bioavailability is estimated to be high, though precise quantification can be complex due to its extensive metabolism and enterohepatic recirculation.

Distribution

Following absorption, mefenamic acid is extensively bound to plasma proteins, primarily albumin, with a reported protein binding exceeding 99%. This high degree of binding limits the free, pharmacologically active fraction of the drug in plasma. The apparent volume of distribution (V_d) is relatively low, approximately 1.0 to 1.5 L/kg, indicating that the drug is largely confined to the plasma and extracellular fluid compartments rather than extensively distributing into tissues. It crosses the placenta and is excreted in breast milk, albeit in low concentrations.

Metabolism

Mefenamic acid undergoes extensive hepatic metabolism, primarily via Phase I oxidative reactions catalyzed by cytochrome P450 (CYP) enzymes, with CYP2C9 being the principal isoform involved. The major metabolites include 3-hydroxymethyl mefenamic acid and 3-carboxymefenamic acid. These metabolites are formed through oxidation of the 3-methyl group on the dimethylphenyl ring. The 3-hydroxymethyl metabolite may undergo further oxidation to the carboxylic acid derivative. These metabolites are considered to possess minimal, if any, anti-inflammatory activity compared to the parent compound. The metabolism is saturable at higher doses, which can lead to non-linear pharmacokinetics and a disproportionate increase in plasma concentrations with dose escalation.

Excretion

Elimination occurs predominantly via the renal route. However, less than 5% of an administered dose is excreted unchanged in the urine. The majority of the drug is eliminated as glucuronide conjugates of the parent compound and its oxidative metabolites. Approximately 50-60% of a dose is recovered in the urine as conjugates, and about 20-30% is excreted in the feces, partly due to biliary excretion of conjugates and subsequent deconjugation in the intestine, leading to enterohepatic recirculation. This recirculation may contribute to the persistence of the drug in the body and potentially to local gastrointestinal toxicity.

Half-life and Dosing Considerations

The elimination half-life (t_1/2) of mefenamic acid is relatively short, ranging from 2 to 4 hours in most individuals. This pharmacokinetic characteristic necessitates a multiple-dosing regimen to maintain therapeutic plasma concentrations throughout the day. The standard adult dosing for pain or primary dysmenorrhea is 500 mg as an initial loading dose, followed by 250 mg every 6 hours as needed. Therapy for dysmenorrhea is typically initiated at the onset of menses and continued for 2 to 3 days. For other painful conditions, treatment is usually recommended for no more than 7 days due to the increased risk of adverse effects with prolonged use. The short half-life implies that steady-state concentrations are achieved rapidly, usually within a day of regular dosing. However, the saturable metabolism means that clearance may decrease at higher doses or with repeated dosing, potentially increasing exposure.

Therapeutic Uses/Clinical Applications

The use of mefenamic acid is approved for specific, short-term indications. Its application is guided by its efficacy profile and the risk-benefit balance associated with NSAID therapy.

Approved Indications

• Mild to Moderate Pain: Mefenamic acid is indicated for the short-term relief of mild to moderate pain in patients aged 14 years and older. This includes pain associated with conditions such as musculoskeletal disorders, dental procedures, headaches, and soft tissue injuries. The duration of treatment for pain should generally not exceed one week.
• Primary Dysmenorrhea: This is a primary and well-established indication for mefenamic acid. Dysmenorrhea is characterized by painful uterine cramps during menstruation, largely mediated by elevated endometrial prostaglandins. Mefenamic acid’s inhibition of prostaglandin synthesis in the uterus effectively reduces the intensity and duration of menstrual pain. It is often initiated at the beginning of menses and continued for the first 2-3 days, coinciding with the period of greatest discomfort.

Off-Label Uses

While not formally approved for these conditions, mefenamic acid has been used or studied in other contexts, though often with less robust evidence or in favor of other agents.

• Menorrhagia (Heavy Menstrual Bleeding): Some evidence suggests that mefenamic acid can reduce menstrual blood loss, likely by decreasing endometrial prostaglandin levels that contribute to excessive bleeding. It may be considered as a therapeutic option, particularly when menorrhagia coexists with dysmenorrhea.
• Inflammatory Conditions: Its anti-inflammatory properties theoretically make it applicable to conditions like rheumatoid arthritis or osteoarthritis. However, due to its short half-life requiring frequent dosing and its association with a higher incidence of certain adverse effects (notably diarrhea), it is rarely a first-line choice for chronic inflammatory arthropathies. Other NSAIDs with more convenient dosing or better-tolerated profiles are typically preferred.
• Patent Ductus Arteriosus (PDA): Intravenous formulations of other NSAIDs (e.g., ibuprofen, indomethacin) are standard for pharmacologic closure of PDA in preterm neonates. While oral mefenamic acid has been investigated for this purpose, it is not a standard therapy.

Adverse Effects

The adverse effect profile of mefenamic acid is consistent with the class effects of non-selective NSAIDs, with some effects being more prominent with fenamates.

Common Side Effects

These effects are often dose-related and may diminish with continued use or with administration alongside food.

• Gastrointestinal: The most frequent adverse reactions involve the GI tract. These include dyspepsia, epigastric pain, nausea, vomiting, and abdominal discomfort. A distinctive and relatively common side effect associated with fenamates, including mefenamic acid, is diarrhea, which may occur in a significant minority of patients and can sometimes be severe enough to necessitate discontinuation of therapy.
• Central Nervous System: Dizziness, headache, nervousness, and drowsiness have been reported.
• Dermatological: Skin rash and pruritus may occur.

Serious/Rare Adverse Reactions

These reactions require immediate medical attention and often warrant discontinuation of the drug.

• Gastrointestinal Toxicity: Serious GI events include peptic ulceration, gastrointestinal bleeding, perforation, and obstruction. These can occur at any time during therapy, with or without warning symptoms, and carry a risk of fatality. The risk is increased with longer duration of use, higher doses, advanced age, history of ulcer disease, concomitant use of corticosteroids, anticoagulants, or other NSAIDs, smoking, and alcohol consumption.
• Cardiovascular Thrombotic Events: As with all NSAIDs (except aspirin at antiplatelet doses), mefenamic acid use may be associated with an increased risk of serious and potentially fatal cardiovascular thrombotic events, including myocardial infarction and stroke. This risk may increase with duration of use and in patients with pre-existing cardiovascular disease or risk factors.
• Renal Toxicity: NSAID use can cause dose-dependent reduction in prostaglandin-mediated renal blood flow, potentially leading to renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and acute kidney injury. Patients with pre-existing renal impairment, heart failure, liver cirrhosis, volume depletion, or those taking diuretics or ACE inhibitors are at heightened risk.
• Hepatic Effects: Borderline elevations of liver function tests may occur. Rare cases of severe hepatic reactions, including jaundice, fulminant hepatitis, and liver failure, have been reported with NSAIDs, including mefenamic acid.
• Hematological Effects: Anemia due to GI blood loss or other mechanisms can occur. Rarely, agranulocytosis, aplastic anemia, hemolytic anemia, and thrombocytopenia have been reported.
• Severe Skin Reactions: Exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported rarely but are potentially life-threatening.
• Allergic Reactions: Anaphylactoid reactions may occur in patients with or without a known hypersensitivity to NSAIDs. Mefenamic acid is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, as severe, potentially fatal bronchospasm may occur.

Boxed Warnings

Mefenamic acid, like other NSAIDs, carries boxed warnings mandated by regulatory authorities such as the U.S. Food and Drug Administration (FDA). These highlight the most significant risks.

• Gastrointestinal Risk: NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious GI events.
• Cardiovascular Risk: NSAIDs may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
• Renal Risk: NSAID use in patients with advanced renal disease is contraindicated. Long-term use can lead to renal papillary necrosis and other renal injury.

Drug Interactions

Mefenamic acid’s high protein binding, metabolism via CYP2C9, and pharmacodynamic effects create potential for significant interactions.

Major Drug-Drug Interactions

• Anticoagulants (Warfarin, Heparins, Direct Oral Anticoagulants): Mefenamic acid may increase the risk of bleeding through several mechanisms: inhibition of platelet aggregation (antiplatelet effect), potential displacement of warfarin from plasma protein binding sites (increasing free warfarin concentration), and causing gastric erosions. Concomitant use requires extreme caution and frequent monitoring of coagulation parameters.
• Other NSAIDs and Aspirin: Concurrent use of two or more NSAIDs, including aspirin at analgesic/anti-inflammatory doses, increases the risk of GI toxicity (ulcers, bleeding) and renal impairment without providing additional therapeutic benefit. Low-dose aspirin for cardioprotection may be used with caution, but the GI risk is additive.
• Corticosteroids (e.g., Prednisone): Significantly increase the risk of GI ulceration and bleeding.
• Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Concomitant use may increase the risk of gastrointestinal bleeding.
• Diuretics, ACE Inhibitors, and Angiotensin II Receptor Blockers (ARBs): NSAIDs can reduce the natriuretic and antihypertensive effects of diuretics and antihypertensive agents. More importantly, they can impair renal function in patients dependent on renal prostaglandins to maintain renal perfusion (e.g., those with heart failure, cirrhosis, or volume depletion), potentially leading to acute kidney injury. This interaction is particularly dangerous with potassium-sparing diuretics, as hyperkalemia may result.
• Lithium: NSAIDs can decrease renal clearance of lithium, leading to increased plasma lithium levels and potential lithium toxicity. Close monitoring of lithium serum concentrations is essential.
• Methotrexate: NSAIDs may reduce the renal clearance of methotrexate, potentially increasing methotrexate levels and the risk of its hematological and gastrointestinal toxicity, particularly with high-dose methotrexate therapy.
• Cyclosporine and Tacrolimus: Increased risk of nephrotoxicity when combined with NSAIDs.
• CYP2C9 Inhibitors and Inducers: Drugs that inhibit CYP2C9 (e.g., fluconazole, amiodarone) may decrease the metabolism of mefenamic acid, potentially increasing its plasma levels and risk of toxicity. Inducers of CYP2C9 (e.g., rifampin) may increase metabolism, reducing its efficacy.

Contraindications

Mefenamic acid is contraindicated in the following situations:

• Known hypersensitivity to mefenamic acid, any component of the formulation, or other NSAIDs (manifested by asthma, rhinitis, urticaria, or other allergic reactions).
• History of asthma, urticaria, or allergic-type reactions precipitated by aspirin or other NSAIDs.
• In the setting of coronary artery bypass graft (CABG) surgery.
• Active peptic ulcer disease or a history of recurrent ulceration or gastrointestinal bleeding.
• Inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis).
• Significant renal impairment or advanced kidney disease.
• Severe hepatic impairment or active liver disease.
• Third trimester of pregnancy due to risk of premature closure of the fetal ductus arteriosus.
• Concomitant use with other NSAIDs, including COX-2 selective inhibitors.

Special Considerations

The use of mefenamic acid requires careful evaluation in specific patient populations due to altered pharmacokinetics, pharmacodynamics, or increased susceptibility to adverse effects.

Pregnancy and Lactation

Pregnancy: NSAID use during pregnancy requires careful risk-benefit assessment. Mefenamic acid is classified as Pregnancy Category C by the FDA (under the old classification system) or is generally not recommended, especially in the third trimester. During the first and second trimesters, use should be limited and at the lowest effective dose for the shortest duration possible if clearly needed. Use during the third trimester is contraindicated because NSAIDs may cause premature closure of the fetal ductus arteriosus, leading to pulmonary hypertension in the neonate. Prolonged use may also inhibit uterine contractions and delay parturition. Oligohydramnios and neonatal renal impairment have also been associated with NSAID use late in pregnancy.

Lactation: Mefenamic acid is excreted in human milk in low concentrations. Because of the potential for serious adverse reactions in nursing infants from NSAIDs, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. The use of alternative agents may be preferred.

Pediatric Considerations

The safety and effectiveness of mefenamic acid in children under 14 years of age have not been established. For adolescents aged 14 and older, dosing for pain or dysmenorrhea follows adult guidelines. Pediatric patients may be more susceptible to certain adverse effects, such as dehydration from diarrhea, which is a notable side effect of fenamates. Use should be for the shortest possible duration and with adequate hydration monitoring.

Geriatric Considerations

Elderly patients (≥65 years) represent a population at increased risk for adverse events from NSAID therapy. Age-related declines in renal and hepatic function can alter drug clearance. The prevalence of comorbid conditions (e.g., hypertension, heart failure, renal impairment, peptic ulcer history) and concomitant use of multiple medications (e.g., anticoagulants, diuretics) significantly elevates the risk of GI bleeding, cardiovascular events, and renal toxicity. If mefenamic acid is used in this population, it should be initiated at the low end of the dosing range, used for the shortest possible duration, and patients should be closely monitored for signs of GI bleeding, renal dysfunction, and fluid retention.

Renal Impairment

NSAIDs are not recommended in patients with significant renal impairment (e.g., creatinine clearance <30 mL/min). In mild to moderate renal impairment, use requires caution. Renal prostaglandins play a compensatory role in maintaining renal blood flow and glomerular filtration rate (GFR) when renal function is compromised. Inhibition of these prostaglandins by mefenamic acid can precipitate acute kidney injury or worsen pre-existing renal disease. Dosing adjustments are not well-defined, but therapy should be initiated at a reduced dose if deemed necessary, and renal function should be monitored regularly. The drug is contraindicated in advanced renal disease.

Hepatic Impairment

Patients with hepatic impairment may have reduced capacity to metabolize mefenamic acid, potentially leading to drug accumulation and increased risk of adverse effects, including hepatotoxicity. Borderline elevations of liver enzymes are common with NSAID use. In patients with pre-existing liver disease (e.g., cirrhosis), the use of NSAIDs can precipitate hepatic decompensation and increase the risk of GI bleeding due to coagulopathy and portal hypertension. Mefenamic acid should be used with extreme caution, if at all, in patients with hepatic impairment, starting at the lowest possible dose and with close monitoring of liver function tests. It is contraindicated in severe hepatic impairment.

Summary/Key Points

• Mefenamic acid is a non-selective, reversible cyclooxygenase (COX) inhibitor belonging to the fenamate (anthranilic acid derivative) class of NSAIDs, with potential additional activity as a prostaglandin EP₁ receptor antagonist.
• Its pharmacokinetics are characterized by rapid oral absorption, high plasma protein binding (>99%), extensive hepatic metabolism primarily via CYP2C9, and a short elimination half-life (2-4 hours) necessitating dosing every 6 hours.
• Approved indications are limited to the short-term (≤7 days) treatment of mild to moderate pain and the management of primary dysmenorrhea, for which it is often a drug of choice.
• The adverse effect profile includes common gastrointestinal disturbances (notably diarrhea), and carries boxed warnings for serious gastrointestinal, cardiovascular, and renal risks shared by the NSAID class.
• Significant drug interactions exist with anticoagulants, other NSAIDs, antihypertensives, diuretics, lithium, and methotrexate, largely due to pharmacodynamic synergism or protein binding displacement.
• Use is contraindicated in patients with NSAID hypersensitivity, active peptic ulcer disease, severe renal/hepatic impairment, during CABG recovery, and in the third trimester of pregnancy.
• Special caution is required in the elderly and in patients with any degree of renal or hepatic impairment, cardiovascular disease, or dehydration, where the risks of therapy are substantially increased.

Clinical Pearls

• Mefenamic acid’s distinctive propensity to cause diarrhea can be a limiting side effect and should be inquired about during patient follow-up.
• For dysmenorrhea, instructing patients to initiate therapy at the very onset of menses (or even prophylactically if timing is predictable) provides optimal efficacy.
• Given its short half-life, missed doses have a relatively rapid impact on declining drug levels, but this also means adverse effects related to accumulation are less likely with appropriate dosing intervals compared to long-half-life NSAIDs.
• The principle of using the lowest effective dose for the shortest possible duration is paramount with mefenamic acid, as with all NSAIDs, to mitigate class-associated risks.
• Concurrent use of a proton pump inhibitor (PPI) or misoprostol may be considered for patients at high risk for GI complications if prolonged therapy is unavoidable, though this does not eliminate the risk.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.